CIK 0001178670
ALNY ALNYLAM PHARMACEUTICALS, INC.
Insider trading from SEC Form 4. Last filing Dec 13, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company
Signals
Open-market buys and sells at ALNYLAM PHARMACEUTICALS, INC., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 17Weak | sell10b5-1 | Garg Pushkal CMO & EVP Dev & Med Affairs | $440k | 1,752 | -10% | - | |
| 37Weak | sell 510b5-1 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | $755k | 3,000 | -19% | - | |
| 50Moderate | sell 5 | Tanguler Tolga EVP, Chief Commercial Officer | $369k | 1,469 | -10% | - | |
| 53Moderate | sell 5 | Poulton Jeffrey V. EVP, Chief Financial Officer | $422k | 1,682 | -5% | - | |
| 46Moderate | sell 5 | Garg Pushkal CMO & EVP Dev & Med Affairs | $422k | 1,682 | -9% | - | |
| 65Notable | sell 5 | Greenstreet Yvonne Chief Executive Officer | $1.3M | 5,219 | -6% | - |
Congressional trades
2 trades in ALNY disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Cory A. Booker Senate · D-NJ | Sale | ALNY Alnylam Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Aug 11, 2026 | 29 days after the trade |
| Jefferson Shreve House · R-IN | Sale | ALNY Alnylam Pharmaceuticals, Inc. - Common Stock | $15k to $50k | May 12, 2025 | 41 days after the trade |
Transactions
The last 41 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock10b5-1 | -121 | $247.48 | $30k | 17,336 | Dec 13, 2024 |
| Dec 12, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock10b5-1 | -186 | $248.99 | $46k | 17,150 | Dec 13, 2024 |
| Dec 12, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock10b5-1 | -426 | $250.08 | $107k | 16,724 | Dec 13, 2024 |
| Dec 12, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock10b5-1 | -778 | $251.68 | $196k | 15,946 | Dec 13, 2024 |
| Dec 12, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock10b5-1 | -100 | $252.94 | $25k | 15,846 | Dec 13, 2024 |
| Dec 12, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock10b5-1 | -140 | $254.37 | $36k | 15,706 | Dec 13, 2024 |
| Dec 12, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock10b5-1 | -1 | $255.80 | $256 | 15,705 | Dec 13, 2024 |
| Nov 25, 2024 | Greenstreet Yvonne Chief Executive Officer | AGrant or award Common Stock | +10,658 | $0.00 | $0 | 84,099 | Nov 27, 2024 |
| Nov 25, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | AGrant or award Common Stock | +3,434 | $0.00 | $0 | 19,139 | Nov 27, 2024 |
| Nov 25, 2024 | Poulton Jeffrey V. EVP, Chief Financial Officer | AGrant or award Common Stock | +3,434 | $0.00 | $0 | 32,326 | Nov 27, 2024 |
| Nov 25, 2024 | Tanguler Tolga EVP, Chief Commercial Officer | AGrant or award Common Stock | +3,000 | $0.00 | $0 | 14,660 | Nov 27, 2024 |
| Nov 25, 2024 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | AGrant or award Common Stock10b5-1 | +3,000 | $0.00 | $0 | 15,881 | Nov 27, 2024 |
| Nov 26, 2024 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | SOpen-market sale Common Stock10b5-1 | -26 | $247.77 | $6,442 | 15,855 | Nov 27, 2024 |
| Nov 26, 2024 | Tanguler Tolga EVP, Chief Commercial Officer | SOpen-market sale Common Stock | -26 | $247.77 | $6,442 | 14,634 | Nov 27, 2024 |
| Nov 26, 2024 | Greenstreet Yvonne Chief Executive Officer | SOpen-market sale Common Stock | -93 | $247.77 | $23k | 84,006 | Nov 27, 2024 |
| Nov 26, 2024 | Poulton Jeffrey V. EVP, Chief Financial Officer | SOpen-market sale Common Stock | -30 | $247.77 | $7,433 | 32,296 | Nov 27, 2024 |
| Nov 26, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock | -30 | $247.77 | $7,433 | 19,109 | Nov 27, 2024 |
| Nov 26, 2024 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | SOpen-market sale Common Stock10b5-1 | -215 | $249.60 | $54k | 15,640 | Nov 27, 2024 |
| Nov 26, 2024 | Tanguler Tolga EVP, Chief Commercial Officer | SOpen-market sale Common Stock | -215 | $249.60 | $54k | 14,419 | Nov 27, 2024 |
| Nov 26, 2024 | Greenstreet Yvonne Chief Executive Officer | SOpen-market sale Common Stock | -762 | $249.60 | $190k | 83,244 | Nov 27, 2024 |
| Nov 26, 2024 | Poulton Jeffrey V. EVP, Chief Financial Officer | SOpen-market sale Common Stock | -246 | $249.60 | $61k | 32,050 | Nov 27, 2024 |
| Nov 26, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock | -246 | $249.60 | $61k | 18,863 | Nov 27, 2024 |
| Nov 26, 2024 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | SOpen-market sale Common Stock10b5-1 | -318 | $250.68 | $80k | 15,322 | Nov 27, 2024 |
| Nov 26, 2024 | Greenstreet Yvonne Chief Executive Officer | SOpen-market sale Common Stock | -1,131 | $250.68 | $284k | 82,113 | Nov 27, 2024 |
| Nov 26, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock | -364 | $250.68 | $91k | 18,499 | Nov 27, 2024 |
| Nov 26, 2024 | Poulton Jeffrey V. EVP, Chief Financial Officer | SOpen-market sale Common Stock | -364 | $250.68 | $91k | 31,686 | Nov 27, 2024 |
| Nov 26, 2024 | Tanguler Tolga EVP, Chief Commercial Officer | SOpen-market sale Common Stock | -318 | $250.68 | $80k | 14,101 | Nov 27, 2024 |
| Nov 26, 2024 | Poulton Jeffrey V. EVP, Chief Financial Officer | SOpen-market sale Common Stock | -945 | $251.42 | $238k | 30,741 | Nov 27, 2024 |
| Nov 26, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock | -945 | $251.42 | $238k | 17,554 | Nov 27, 2024 |
| Nov 26, 2024 | Tanguler Tolga EVP, Chief Commercial Officer | SOpen-market sale Common Stock | -826 | $251.42 | $208k | 13,275 | Nov 27, 2024 |
| Nov 26, 2024 | Greenstreet Yvonne Chief Executive Officer | SOpen-market sale Common Stock | -2,933 | $251.42 | $737k | 79,180 | Nov 27, 2024 |
| Nov 26, 2024 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | SOpen-market sale Common Stock10b5-1 | -826 | $251.42 | $208k | 14,496 | Nov 27, 2024 |
| Nov 26, 2024 | Poulton Jeffrey V. EVP, Chief Financial Officer | SOpen-market sale Common Stock | -97 | $252.27 | $24k | 30,644 | Nov 27, 2024 |
| Nov 26, 2024 | Tanguler Tolga EVP, Chief Commercial Officer | SOpen-market sale Common Stock | -84 | $252.27 | $21k | 13,191 | Nov 27, 2024 |
| Nov 26, 2024 | Garg Pushkal CMO & EVP Dev & Med Affairs | SOpen-market sale Common Stock | -97 | $252.27 | $24k | 17,457 | Nov 27, 2024 |
| Nov 26, 2024 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | SOpen-market sale Common Stock10b5-1 | -84 | $252.27 | $21k | 14,412 | Nov 27, 2024 |
| Nov 26, 2024 | Greenstreet Yvonne Chief Executive Officer | SOpen-market sale Common Stock | -300 | $252.27 | $76k | 78,880 | Nov 27, 2024 |
| Nov 27, 2024 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | SOpen-market sale Common Stock10b5-1 | -210 | $250.45 | $53k | 14,202 | Nov 27, 2024 |
| Nov 27, 2024 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | SOpen-market sale Common Stock10b5-1 | -851 | $251.98 | $214k | 13,351 | Nov 27, 2024 |
| Nov 27, 2024 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | SOpen-market sale Common Stock10b5-1 | -360 | $253.44 | $91k | 12,991 | Nov 27, 2024 |
| Nov 27, 2024 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | SOpen-market sale Common Stock10b5-1 | -110 | $254.48 | $28k | 12,881 | Nov 27, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Fitzgerald Kevin JosephCSO & EVP, Head of Research
- Garg PushkalCMO & EVP Dev & Med Affairs
- Greenstreet YvonneChief Executive Officer
- Poulton Jeffrey V.EVP, Chief Financial Officer
- Tanguler TolgaEVP, Chief Commercial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.